Exact Sciences EXAS · NASDAQ
$104.91 +0.00% (+$0.00)
Summary
24 / 100 · Bulios Score
What speaks for it
- Revenue grew by 19% a year over the last 3 years.
- Out of every 100 USD of revenue, 11 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 36.8 years of operating profit.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
- Analyst estimate
Revenue grew by 17% a year over 5 years. Over the last 3 years it grew by 19% a year.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt. The debt score is low because of the debt-to-equity ratio (1.1x).
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 22
- Hold 17
- Sell 2
No analyst has published a price target.
54% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.